Simon S Jones
Overview
Explore the profile of Simon S Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
889
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maharaj K, Powers J, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, et al.
Front Immunol
. 2020 Dec;
11:590072.
PMID: 33329575
Development of chronic lymphocytic leukemia (CLL) is associated with severe immune dysfunction. T-cell exhaustion, immune checkpoint upregulation, and increase of regulatory T cells contribute to an immunosuppressive tumor microenvironment. As...
2.
Dasmahapatra G, Patel H, Friedberg J, Quayle S, Jones S, Grant S
Mol Cancer Ther
. 2019 Jun;
18(6):1181.
PMID: 31160511
No abstract available.
3.
Maharaj K, Powers J, Achille A, Deng S, Fonseca R, Pabon-Saldana M, et al.
Blood Adv
. 2018 Nov;
2(21):3012-3024.
PMID: 30425065
Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist...
4.
Adeegbe D, Liu Y, Lizotte P, Kamihara Y, Aref A, Almonte C, et al.
Cancer Discov
. 2017 Apr;
7(8):852-867.
PMID: 28408401
Effective therapies for non-small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways. It is now clear that therapeutic agents with potential to...
5.
North B, Almeciga-Pinto I, Tamang D, Yang M, Jones S, Quayle S
PLoS One
. 2017 Mar;
12(3):e0173507.
PMID: 28264055
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including...
6.
Min C, Moore N, Shearstone J, Quayle S, Huang P, van Duzer J, et al.
PLoS One
. 2017 Jan;
12(1):e0169128.
PMID: 28060870
Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic stem cell disorders characterized by defects in myeloid differentiation and increased proliferation of neoplastic hematopoietic precursor cells. Outcomes for patients...
7.
Vogl D, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, et al.
Clin Cancer Res
. 2017 Jan;
23(13):3307-3315.
PMID: 28053023
Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity. Preclinical models suggest that the observed synergy is due to the role of...
8.
Huang P, Almeciga-Pinto I, Jarpe M, van Duzer J, Mazitschek R, Yang M, et al.
Oncotarget
. 2016 Dec;
8(2):2694-2707.
PMID: 27926524
ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242). Like the structurally related drug ACY-1215 (ricolinostat),...
9.
Yee A, Bensinger W, Supko J, Voorhees P, Berdeja J, Richardson P, et al.
Lancet Oncol
. 2016 Sep;
17(11):1569-1578.
PMID: 27646843
Background: Histone deacetylase (HDAC) inhibitors are an important new class of therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC...
10.
Shearstone J, Golonzhka O, Chonkar A, Tamang D, van Duzer J, Jones S, et al.
PLoS One
. 2016 Apr;
11(4):e0153767.
PMID: 27073918
Therapeutic intervention aimed at reactivation of fetal hemoglobin protein (HbF) is a promising approach for ameliorating sickle cell disease (SCD) and β-thalassemia. Previous studies showed genetic knockdown of histone deacetylase...